Global Pharmaceutical Market Outlook, 2031

The global pharmaceutical industry covers the research, development, manufacturing and sale of prescription medicines, over-the-counter medicines, generics, biosimilars and vaccines used to prevent and treat disease. Worldwide spending on medicines is well above USD 1.5 trillion a year, according to IQVIA, and the industry is one of the most research-intensive in the world. It is led by large multinational companies, including Eli Lilly, Johnson & Johnson, Roche, Merck, AbbVie, Pfizer, AstraZeneca, Novartis, Novo Nordisk, Bristol Myers Squibb, Sanofi, GSK, Amgen, Gilead, Takeda, Boehringer Ingelheim, Bayer, Regeneron, Vertex and Daiichi Sankyo, alongside generic and biosimilar manufacturers such as Teva, Sandoz, Viatris, Sun Pharma, Dr. Reddy's, Cipla, Lupin, Aurobindo, Hikma, Celltrion and Samsung Bioepis, and a large contract development and manufacturing sector led by Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher and Catalent, now owned by Novo Holdings. The United States accounts for the largest share of spending and is the main launch market for new medicines, while India and China are major suppliers of generic medicines and active pharmaceutical ingredients. Oncology, immunology, metabolic diseases including obesity and diabetes, neurology and infectious diseases are the largest therapeutic areas.

The industry has passed through several major shifts since 2020. The COVID-19 pandemic produced record sales of vaccines and antivirals for Pfizer, Moderna, BioNTech and others, followed by a sharp decline from 2023. The rise of GLP-1 drugs for diabetes and obesity then created the fastest-growing product class in pharmaceutical history, making Eli Lilly the first pharmaceutical company to reach a market value of USD 1 trillion in November 2025. Policy in the United States has become the central uncertainty. The Inflation Reduction Act introduced Medicare drug price negotiation, with the first negotiated prices taking effect in January 2026 and a second round, covering drugs including Ozempic, announced in November 2025. In 2025 the US administration pursued most-favoured-nation pricing, securing agreements with Pfizer in September 2025 and later with many other companies, and launched TrumpRx.gov in February 2026 for direct cash purchases. In April 2026 it imposed Section 232 tariffs of up to 100% on imported patented medicines, with exemptions and lower rates for companies with pricing and onshoring agreements and for the EU, Japan, the UK and other partners. Companies announced hundreds of billions of dollars of US manufacturing investment in response. At the same time, the industry faces a large patent cliff between 2026 and 2030, affecting drugs such as Keytruda, Eliquis, Opdivo and Darzalex, and increasingly licenses innovative drugs from Chinese biotechnology companies.

Market Dynamics Market Drivers • Ageing Populations and Chronic Disease BurdenAgeing populations, rising rates of obesity, diabetes, cardiovascular disease, cancer and neurological disorders, and expanding access to healthcare in emerging markets increase demand for medicines worldwide. Older people take more medicines and for longer periods, and chronic diseases require long-term treatment. Growing middle classes and expanded insurance coverage in China, India, Southeast Asia, Latin America and the Middle East add to demand.
• Scientific Innovation and New Therapeutic ClassesAdvances in biology, genomics and technology have produced new classes of medicines, including GLP-1 and multi-agonist obesity drugs, antibody-drug conjugates, bispecific antibodies, cell and gene therapies, RNA medicines and targeted protein degraders. These innovations address previously untreatable conditions and command premium prices. Artificial intelligence is increasingly used in drug discovery and clinical development, potentially shortening timelines and improving success rates.

Market Challenges • Pricing Pressure and Policy UncertaintyGovernments and payers are intensifying efforts to control drug spending. In the United States, Medicare price negotiation, most-favoured-nation pricing agreements, PBM reform and tariffs are changing the economics of the largest pharmaceutical market. European health technology assessment and reference pricing, China's volume-based procurement and national reimbursement negotiations, and Japan's regular price cuts put further pressure on prices, while tariffs and trade tensions complicate global supply chains.
• Patent Expiries and Rising R&D CostsMany of the industry's best-selling drugs lose exclusivity between 2026 and 2030, exposing a large share of revenue to generic and biosimilar competition. Developing a new medicine costs billions of dollars and takes a decade or more, with most candidates failing in clinical trials. Companies must replace lost revenue through internal research, licensing and acquisitions, increasing competition for promising assets and raising deal prices.

Market Trends • US Manufacturing Investment and Supply Chain ReshoringIn response to tariffs, pricing agreements and supply security concerns, pharmaceutical companies have announced large investments in US manufacturing, including new plants for active ingredients, biologics and GLP-1 drugs by Lilly, Johnson & Johnson, AstraZeneca, Roche, Novartis, Sanofi, Merck and others. Governments in Europe, India and elsewhere are also promoting domestic production of critical medicines and ingredients to reduce dependence on single countries.
• Licensing from China and Global Deal-MakingChinese biotechnology companies have become a major source of new drug candidates, especially bispecific antibodies, antibody-drug conjugates and obesity drugs, and a growing share of large pharmaceutical licensing deals involve assets from China. Big pharmaceutical companies are also acquiring US and European biotechnology companies to fill pipelines ahead of patent expiries, with multibillion-dollar deals in obesity, neuroscience, immunology and oncology during 2025 and 2026.



Segment Analysis Branded prescription drugs account for the largest share of pharmaceutical value, while generics account for the largest share of volume and biosimilars are the fastest-growing off-patent segment. Branded prescription drugs, protected by patents and regulatory exclusivity, generate most pharmaceutical revenue, particularly in the United States, where branded drugs account for a small share of prescriptions but most spending. They include small molecules and biologics across oncology, immunology, metabolic, cardiovascular, neurology and infectious diseases. Generic drugs, copies of small-molecule medicines after patent expiry, account for about 90% of US prescriptions and a large share of volume worldwide, supplied mainly by Indian, Chinese, European and US manufacturers at low prices. Biosimilars, highly similar versions of biologic drugs, have grown rapidly in Europe and increasingly in the United States, with major launches for adalimumab, ustekinumab, denosumab and aflibercept. Over-the-counter medicines, including pain relievers, cold and allergy products, digestive products and vitamins, are sold without prescription through pharmacies and retailers, led by consumer health companies such as Haleon, Kenvue, Bayer and Sanofi's Opella. Vaccines form a distinct segment led by Pfizer, Merck, GSK and Sanofi, with COVID-19 vaccine sales now far below their peak. Specialty drugs, including high-cost treatments for cancer, rare diseases and immunology, account for a growing share of spending. Cell and gene therapies and RNA medicines are small but fast-growing segments.

Small molecules still account for the largest number of approved medicines, while biologics and newer modalities generate a rising share of pharmaceutical revenue and new approvals. Small-molecule drugs, chemically synthesised compounds usually taken as tablets or capsules, remain the majority of medicines by number and prescription volume, and they continue to produce important new drugs, including oral targeted cancer drugs, oral GLP-1 agonists such as orforglipron and new cardiovascular and neurology drugs. Biologics, including monoclonal antibodies, therapeutic proteins, peptides, insulins and vaccines, account for a rising share of revenue, and many of the world's best-selling drugs, such as Keytruda, Dupixent, Skyrizi and semaglutide, are biologics or peptides. Antibody-drug conjugates and bispecific antibodies are among the fastest-growing biologic classes. Nucleic acid therapies, including antisense oligonucleotides, siRNA and mRNA, treat genetic diseases, cardiovascular disease and infectious diseases. Cell therapies, including CAR-T therapies, and gene therapies and gene editing offer potentially one-time treatments. Radiopharmaceuticals, such as Novartis's Pluvicto, have become a growing oncology segment. Peptides have become especially important with the growth of obesity and diabetes drugs. The shift toward complex modalities requires specialised manufacturing and has increased demand for contract manufacturers.

Oncology is the largest therapeutic area by pharmaceutical spending, while metabolic diseases including obesity have been the fastest-growing area, and immunology remains a major segment. Oncology is the largest therapeutic area, accounting for about a fifth of global drug spending, driven by immunotherapies, targeted therapies, antibody-drug conjugates, cell therapies and supportive care, with Keytruda the world's best-selling drug. Metabolic and endocrine diseases, including diabetes and obesity, have become the fastest-growing area because of GLP-1 and dual agonist drugs, with semaglutide and tirzepatide among the top-selling medicines. Immunology, including treatments for psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma, is a major area led by Dupixent, Skyrizi and Rinvoq, though older biologics face biosimilars. Cardiovascular drugs, including anticoagulants, lipid-lowering drugs and heart failure treatments, are widely used, with Eliquis a top seller facing patent expiry. Neurology and psychiatry have seen renewed innovation, including Alzheimer's, migraine, multiple sclerosis and schizophrenia drugs. Infectious diseases, including HIV medicines and vaccines, remain significant. Rare diseases are a growing area with high-priced therapies. Respiratory, gastrointestinal, ophthalmology, dermatology, women's health and haematology form further areas.

Hospital and retail pharmacies are the main distribution channels for medicines, while specialty, mail-order and direct-to-consumer channels have grown rapidly. Retail pharmacies, including chains and independent pharmacies, dispense most prescriptions for chronic and acute conditions and sell over-the-counter medicines, and pharmaceutical wholesalers such as McKesson, Cencora and Cardinal Health in the United States, and Phoenix, Alliance Healthcare and others in Europe, supply them. Hospital pharmacies supply medicines used in inpatient and outpatient hospital care, including infused biologics, chemotherapy, anaesthetics and antibiotics, and hospitals are the main channel for many high-value specialty drugs outside the United States. Specialty pharmacies handle high-cost drugs for cancer, immunology, rare diseases and other complex conditions, and in the United States they are often owned by pharmacy benefit managers or health systems. Mail-order and online pharmacies have grown for chronic medicines and in markets such as India and China, where e-pharmacy platforms are expanding. Direct-to-consumer channels, including manufacturer platforms such as LillyDirect and NovoCare and the government's TrumpRx.gov website launched in 2026, have become an important route for cash purchases of obesity drugs and other medicines in the United States. Physician offices and clinics administer injectable drugs. Government tenders supply medicines in many countries.

Regional Analysis North America leads the pharmaceutical market because the United States accounts for the largest share of global drug spending and is the main launch market for new medicines, while Asia-Pacific is the fastest-growing region and a key manufacturing base. North America, led by the United States, accounts for more than 40% of global pharmaceutical spending. The United States has the highest drug prices in the world, rapid adoption of new medicines and a large biotechnology sector, and most new drugs are launched there first. Policy changes are reshaping the market: the first Medicare negotiated prices took effect in January 2026, most-favoured-nation agreements with major manufacturers from September 2025, TrumpRx.gov launched in February 2026, PBM reform was signed into law in February 2026 and Section 232 tariffs on imported patented medicines were announced in April 2026. Canada has a smaller market with lower prices. Europe is the second largest region, home to major companies such as Roche, Novartis, AstraZeneca, GSK, Sanofi, Novo Nordisk, Bayer and Boehringer Ingelheim, with prices controlled by governments and health technology assessment, and the EU has worked on reform of its pharmaceutical legislation. Asia-Pacific is the fastest-growing region. China is the second largest national market and a fast-rising source of innovation, with Chinese biotechnology companies licensing many drugs to Western companies, while volume-based procurement has cut generic prices. Japan is a large mature market with regular price cuts, and India is the world's largest supplier of generic medicines by volume and a major vaccine producer. Latin America, led by Brazil and Mexico, and the Middle East and Africa are growing markets, with Saudi Arabia and the UAE investing in local manufacturing and Africa seeking to build vaccine and medicine production capacity.

Key Developments April 2026: A presidential proclamation set tariffs of up to 100% on imported patented medicines and ingredients, with exemptions for companies with pricing and onshoring agreements and capped rates for the EU, Japan, the UK and others.
February 2026: The US government launched TrumpRx.gov, a website offering discounted cash prices for medicines from manufacturers that signed most-favoured-nation pricing agreements.
January 2026: Medicare began paying negotiated prices for ten drugs, including Eliquis, Xarelto, Jardiance, Januvia and Stelara, under the Inflation Reduction Act.
November 2025: Eli Lilly became the first pharmaceutical company valued at USD 1 trillion, driven by demand for its obesity and diabetes drugs Zepbound and Mounjaro.
November 2025: Medicare announced negotiated prices for 15 more drugs, including semaglutide, taking effect in 2027.
September 2025: Pfizer agreed with the US administration to offer most-favoured-nation prices to Medicaid, sell drugs through TrumpRx and invest in US manufacturing in exchange for tariff relief.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Pharmaceutical Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Branded Prescription Drugs
• Generic Drugs
• Biosimilars
• Over-the-Counter Medicines
• Vaccines

By Molecule Type
• Small Molecules
• Biologics
• Nucleic Acid Therapies
• Cell and Gene Therapies

By Therapeutic Area
• Oncology
• Metabolic and Endocrine Diseases
• Immunology
• Cardiovascular Diseases
• Neurology and Psychiatry
• Infectious Diseases
• Rare Diseases

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Specialty Pharmacies
• Online and Mail-Order Pharmacies
• Direct-to-Consumer Channels